https://orcid.org/0000-0002-1773-6482
References
- Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73
- Ramratnam SK, Bacharier LB, Guilbert TW. Severe asthma in children. J Allergy Clin Immunol Pract 2017;5:889-98
- Bush A, Fleming L, Saglani S. Severe asthma in children. Respirology 2017;22:886-97
- Fitzpatrick AM. Severe asthma in children: lessons learned and future directions. J Allergy Clin Immunol Pract 2016;4:11-19, quiz 20-1
- Fleming L, Murray C, Bansal AT, et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur Respir J 2015;46:1322-33
- Licari A, Brambilla I, De Filippo M, et al. The role of upper airway pathology as a co-morbidity in severe asthma. Expert Rev Respir Med 2017;11:855-65
- Teague WG, Phillips BR, Fahy JV, et al. Baseline features of the Severe Asthma Research Program (SARP III) cohort: differences with age. J Allergy Clin Immunol Pract. 2017. pii: S2213-2198(17)30526-3
- Larenas-Linnemann D, Nieto A, Palomares O, et al. Moving toward consensus on diagnosis and management of severe asthma in children. Curr Med Res Opin 2018;34:447-458
- Ciprandi G, Tosca MA, Silvestri M, Ricciardolo FLM. Inflammatory biomarkers for asthma endotyping and consequent personalized therapy. Expert Rev Clin Immunol 2017;13:715-21
- Sánchez-García S, Habernau Mena A, Quirce S. Biomarkers in inflammometry pediatric asthma: utility in daily clinical practice. Eur Clin Respir J 2017;4:1356160
- Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs 2014;16:491-502
- Licari A, Marseglia G, Castagnoli R, et al. The discovery and development of omalizumab for the treatment of asthma. Expert Opin Drug Discov 2015;10:1033-42
- Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol 2017;139:1431-44
- Saglani S. Childhood severe asthma: new insights on remodelling and biomarkers. Paediatr Respir Rev 2017;24:11-13
- Riccio AM, Mauri P, De Ferrari L, et al. Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months. Clin Transl Allergy 2017;7:6
- Martin Alonso A, Saglani S. Mechanisms mediating pediatric severe asthma and potential novel therapies. Front Pediatr 2017;5:154
- Licari A, Castagnoli R, Brambilla I, et al. New approaches for identifying and testing potential new anti-asthma agents. Expert Opin Drug Discov 2018;13:51-63